Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy for a Cancer Diagnosis [0.03%]
胰十二指肠切除术后非酒精性脂肪肝病的诊断病例报告
Amy E McGhee-Jez,Inna Chervoneva,Misung Yi et al.
Amy E McGhee-Jez et al.
Purpose: Current literature reports increased incidence of postpancreaticoduodenectomy (PD) nonalcoholic fatty liver disease (NAFLD), a precursor for nonalcoholic steatohepatitis and cirrhosis. The incidence of and risk factors (RFs) for NA...
Differentiating Primary Pancreatic Lymphoma Versus Primary Splenic Lymphoma: A Case Report [0.03%]
胰腺原发淋巴瘤和脾脏原发淋巴瘤的鉴别诊断：一例报道
Robert A Ries,Christina L Jacovides,Jennifer Rashti et al.
Robert A Ries et al.
Background: Both primary pancreatic lymphoma (PPL) and primary splenic lymphoma (PSL) represent rare entities. PPL typically arises in the head of the pancreas but may arise in other locations also. PSL usually presents with nonspecific sym...
Robotic Distal Pancreatectomy and Splenectomy for an Intrapancreatic Hepatocellular Carcinoma: A Case Report and Review of the Literature [0.03%]
胰体内肝细胞癌的机器人远端胰腺和脾脏切除术：病例报告及文献回顾
Charles C Vining,Phillip J Hsu,Darryl Schuitevoerder et al.
Charles C Vining et al.
Background: Liver parenchyma that resides outside of the normal hepatic confines is defined as accessory liver if in communication with the native biliary tree, or ectopic liver (EL) if it is not. EL can develop in a variety of tissues, inc...
Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer [0.03%]
对于转移性胰腺癌化疗患者的免疫治疗可获益
Jonathan J Hue,Katherine Bingmer,Kavin Sugumar et al.
Jonathan J Hue et al.
Background: Immunotherapy (IT) has led to improved survival in several common cancers but success in pancreatic ductal adenocarcinoma (PDAC) has been limited. We analyzed if combination IT-chemotherapy (IT-CT) is associated with improved su...
A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer [0.03%]
胰腺癌切除术后应用重组酵母表达突变RAS蛋白GI-4000 II期随机安慰剂对照辅助治疗临床试验
Peter Muscarella,Tanios Bekaii-Saab,Kristi McIntyre et al.
Peter Muscarella et al.
Purpose: GI-4000, a series of recombinant yeast expressing four different mutated RAS proteins, was evaluated in subjects with resected ras-mutated pancreas cancer. Methods: Subjects (n = 176) received GI-4000 or placebo plus gemcitabine. S...
Primary Pancreatic Signet Ring Cell Carcinoma: A Case Report and Review of the Literature [0.03%]
原发性胰腺印戒细胞癌一例报告及文献复习
Daniel J Campbell,Emily L Isch,Geoffrey M Kozak et al.
Daniel J Campbell et al.
Background: Primary pancreatic signet ring cell carcinoma (PPSRCC) is a rare (
Pylorus Preserving Pancreaticoduodenectomy After Prior Esophagogastrectomy [0.03%]
保留幽门的胰十二指肠切除术后的食管胃吻合手术
Rachel Appelbaum,Daniel C Kuehler,Jeffrey Brodsky
Rachel Appelbaum
Background: As treatment of esophageal carcinomas continues to improve, we have seen an increasing population of long-term survivors giving rise to the observation of additional primary malignancies not previously seen. Esophagogastrectomy ...
Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review [0.03%]
DNA修复缺陷型胰腺癌中聚(ADP核糖)多聚酶抑制剂的作用述评
Anup Kasi,Mohammed Al-Jumayli,Robin Park et al.
Anup Kasi et al.
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is the most common cancer found in the pancreas. It has a dismal prognosis and current therapeutic options, including surgical resection, provide only a temporary or limited response due to t...
Marked Decrease in CA 19-9 Level Belies Rapidly Progressive Lymphangitic Carcinomatosis in a Case of Metastatic Pancreatic Cancer [0.03%]
甲胎蛋白水平快速下降掩盖了胰腺癌肺淋巴管浸润型转移病程恶化的一例报告
Daniel A King,Gino Pineda,Iny Jhun et al.
Daniel A King et al.
Background: The CA 19-9 tumor marker is commonly used alongside imaging to trend chemotherapy response in patients with pancreatic ductal adenocarcinoma. Presentation: We describe an unusual clinical case of metastatic pancreatic cancer who...
Factors Associated with Treatment and Survival of Early Stage Pancreatic Cancer in the Era of Modern Chemotherapy: An Analysis of the National Cancer Database [0.03%]
现代化疗时代与早期胰腺癌治疗和生存率相关的因素：全国癌症数据库的分析
Michael D Watson,Jennifer L Miller-Ocuin,Michael R Driedger et al.
Michael D Watson et al.
Background: Underutilization of operative management of early stage pancreatic cancer is associated with sociodemographic variables, including age, race, facility type, insurance, and education. It is currently unclear how these variables a...